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Introduction: Studies of effective psychotherapy for
individuals suffering from the effects of prolonged grief
disorder (PGD) are scarce. This paper describes the
protocol for an evaluation of a metacognitive therapy
programme designed specifically for PGD, to reduce
the psychological distress and loss of functioning
resulting from bereavement.
Methods and analysis: The proposed trial
comprises three phases. Phase 1 consists of a review
of the literature and semistructured interviews with key
members of the target population to inform the
development of a metacognitive therapy programme for
Prolonged Grief. Phase 2 involves a randomised
controlled trial to implement and evaluate the
programme. Male and female adults (N=34) will be
randomly assigned to either a wait list or an
intervention group. Measures of PGD, anxiety,
depression, rumination, metacognitions and quality of
life will be taken pretreatment and posttreatment and at
the 3-month and 6-month follow-up. The generalised
linear mixed model will be used to assess treatment
efficacy. Phase 3 will test the social validity of the
programme.
Discussion: This study is the first empirical
investigation of the efficacy of a targeted metacognitive
treatment programme for PGD. A focus on identifying
and changing the metacognitive mechanisms
underpinning the development and maintenance of
prolonged grief is likely to be beneficial to theory and
practice.
Ethics: Ethics approval was obtained from Curtin
University Human Research Ethics Committee
(Approval number HR 41/2013.)
Trial registration number: ACTRN12613001270707.
INTRODUCTION
It is increasingly argued that a significant
minority of bereaved individuals experience
a more complicated form of grief called pro-
longed grief disorder (PGD) following the
death of a significant other.1–4 Their pro-
longed grief causes significant social and
occupational impairment and is associated
with suicidality, poorer health-related quality
of life, substance abuse2 3 and a reduced like-
lihood to seek assistance from mental health
services.5 These individuals experience
separation distress, involving an unrelenting
yearning for the deceased, a sense of mean-
inglessness, and difficulty accepting the loss,
all of which remain elevated for 6 months or
more following the loss.4–6 Individuals
experiencing PGD also fail to exercise regu-
larly, withdraw from social activities and
neglect their own nutrition.7
Grief was historically excluded from diag-
nostic nosology on the basis that it was an
inevitable and natural response to a traumatic
event.4 However, persistent complex bereave-
ment disorder is a condition for further study
in the latest Diagnostic and Statistical Manual
of Mental Disorders (DSM)8 and PGD is
likely to be included in the forthcoming
International Classification of Diseases
(ICD).9 There is growing empirical evidence
supporting the distinction between normal
and diagnosable grief reactions and attention
has turned to the development of treatments
specifically for PGD.
Grief interventions
The lack of understanding of grief within a
clinical framework has been a barrier to
effective treatment interventions.10 Although
the emphasis on ‘working through’ different
Strengths and limitations of this study
▪ This is the first randomised controlled trial
testing the effectiveness of a targeted metacogni-
tive treatment intervention to reduce prolonged
grief disorder symptomatology.
▪ The study will establish the mechanisms by
which the intervention is effective.
▪ The study will also determine if a short manua-
lised intervention is acceptable for people with
prolonged grief disorder.
▪ If the intervention is not acceptable, this study
will identify the factors contributing to a negative
outcome.
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stages of grief has been challenged in recent years, the
idea remains uncritically accepted by many service provi-
ders,10 and many grief service providers still draw on
stage, task and process models.11 12 Grief interventions
for ‘normal’ grief have not been efficacious and in many
cases have even obstructed grief processes.13
Interventions based on standard treatments for
depression show minimal effects.14 15 However, treat-
ments tailored to PGD symptoms demonstrate better
outcomes.16–18 For example, one study17 compared cog-
nitive behavioural therapy (CBT; 6 sessions of cognitive
restructuring and 6 sessions of exposure therapy) with
12 sessions of supportive counselling (SC). CBT was
found to be more effective than SC, and the exposure
therapy component of CBT was found to be more bene-
ficial than cognitive restructuring, suggesting that avoid-
ance behaviours may be more central to PGD than the
content of thoughts. Similarly, another study18 adapted
interpersonal psychotherapy for depression (IPT) into a
complicated grief treatment (CGT) that targeted depres-
sive symptoms and trauma over 16 sessions. CGT was
found to have significantly greater reductions in symp-
tomatology than IPT alone, providing support for the
need to tailor treatments to symptomatology. However,
only 51% of the intervention group responded to treat-
ment, suggesting more work is required in this area.
The need for an effective treatment for PGD is further
supported by a recent meta-analysis,19 which found that
interventions targeting complications experienced in
grief have only had moderate effect sizes. One of the
possible reasons for the moderate effect sizes may be
that therapies were not based on a theoretical model
underpinning all the symptoms of PGD. The dominant
model is the cognitive behavioural model, which sug-
gests difficulty integrating the loss into autobiographical
knowledge, negative global beliefs, misconceived grief
symptoms and avoidance behaviours underpin the devel-
opment and maintenance of PGD.20 CBT primarily
focuses on exposure to traumatic memories, the repeti-
tive recall of events, behavioural activation and restruc-
turing the content of maladaptive thoughts. While
maladaptive thoughts (eg, ‘I’m not good enough’; ‘I’m
vulnerable’; ‘I’m at threat’) are characteristic of depres-
sion, anxiety and post-traumatic stress disorder (PTSD),
PGD is distinct from these disorders. Although some
overlapping in symptomatology occurs with that of
depression, anxiety and PTSD, symptoms of separation
distress, yearning, disbelief and a sense of meaningless-
ness are unique to PGD.20 21 PGD involves preoccupa-
tion with mental anguish over the reality of the loss and
an inability to consider a future without the deceased.21
The metacognitive model would suggest that treatment
effectiveness may be improved by shifting the focus away
from reappraisal of the content of thoughts to focusing
on modifying unhelpful metacognitive processes under-
stood to maintain distress.22 The death of a loved one
comprises many realistic thoughts involving the events
surrounding the death, shock that the loved one will not
be returning and the financial stressors now faced.
Therefore, addressing how bereaved individuals process
loss-related thoughts may be more effective than addres-
sing what they think.
Studies have identified that some bereaved individuals
ruminate over memories of the deceased in an effort to
‘make sense’ of the death,23 or to ‘properly mourn’ or
to maintain bonds with the deceased.10 24 25
Importantly, studies have clearly demonstrated that
rumination intensifies grief symptoms.26 27 Rumination
has been shown to be an anxious avoidant coping strat-
egy, whereby events in the past and counterfactual
thoughts (eg, ‘what if I’d stayed home that day’) are
rehashed by the bereaved to avoid emotions and
thoughts related to the reality of the loss.28 29
Rumination, postevent processing and worry have a
common underlying construct called repetitive negative
thinking, which has recently been identified as a trans-
diagnostic process.30–32 Repetitive negative thinking
about issues related to past experiences or worries about
the future30 keeps attention fixed on distressing informa-
tion (eg, the injustice and consequences of the loss),
which impairs the chance of developing coping strat-
egies, promotes maladaptive behaviours, drives away
social support and perpetuates depressive symptoms.33 34
A recent study35 found individuals with low social
support ruminated more, causing higher levels of PGD
symptoms and lower levels of positive mood. For grief
treatment to be effective, it is important that techniques
are grounded within an information processing frame-
work that targets the way distressing information is pro-
cessed, to prevent people developing maladaptive
coping processes (eg, rumination and worry). The meta-
cognitive model posits metacognitions give rise to mal-
adaptive patterns of thinking.36 Therefore, a treatment
based on a metacognitive model may be better suited to
PGD, as this model targets the way information is pro-
cessed rather than focusing on the content of thoughts.
The metacognitive model of psychological disorder
The metacognitive model suggests psychological disor-
ders result from repetitive negative thinking over a per-
ceived belief (eg, the world is dangerous), creating an
attentional bias due to a constant focus on and monitor-
ing of this belief.22 Therefore, individuals with a high
level of repetitive negative thinking are less likely to
develop coping strategies and more likely to develop a
cognitive attentional syndrome. The cognitive atten-
tional syndrome, comprising worry/rumination, threat
monitoring and maladaptive coping behaviours, has
been found to intensify and prolong psychological dis-
tress.36 Metacognitive beliefs about the function of these
coping processes maintain the cognitive attentional syn-
drome.36 Given that rumination is a key factor identified
in the development and maintenance of PGD, a meta-
cognitive model of psychological disorder would suggest
that modification of this dysfunctional thinking style
would be essential in treating this condition.
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Metacognitive therapy (MCT) alters a dysfunctional
thinking style by helping individuals understand their
‘thoughts about thoughts’ and regulate unhelpful
thoughts and feelings. It uses detached mindfulness to
educate people to be ‘mindful’ of thoughts, emotions,
beliefs and memories without exclusively focusing on
them, and to help people see themselves as separate to
their thoughts.36 MCT deals with intrusive symptoms,
allowing individuals to shift from self-processing by
interrupting negative thoughts and gaining a flexible
non-repetitive thinking style.36 This model comple-
ments the dominant model of grief which proposes
that the moving between loss and restoration domains
allows the grieving individual to gradually accommodate
the loss.37
Efficacy of metacognitive treatment
Efficacy of MCT has been demonstrated in studies of
major depressive disorder;38–40 obsessive-compulsive dis-
order;41–43 social phobia;44 45 generalised anxiety dis-
order;46 47 and PTSD.48–50 Wells et al40 evaluated the
effectiveness of eight sessions of MCT with a sample of
12 patients with treatment-resistant recurrent Major
Depressive Disorder and found large and clinically sig-
nificant reductions in attentional control, rumination,
worry and metacognitive beliefs that were maintained at
the 6-month and 12-month follow-ups. The 12-month
follow-up revealed that 80% of patients had recovered;
suggesting MCT is an effective treatment for patients
non-responsive to antidepressant medication and previ-
ous psychological treatments. Moreover, the effective-
ness of MCT for chronic PTSD was recently supported
in a controlled trial48 with 20 patients revealing signifi-
cant reductions in PTSD symptoms, anxiety and depres-
sion in the MCT group at post-test and at the 3-month
and 6-month follow-up, with recovery rates of 60–80%
maintained at the 6-month follow-up. These studies
demonstrate that MCT is effective in helping patients
respond to intrusive and dysfunctional thoughts. Also,
excellent outcomes with MCT have been achieved in as
little as six sessions, indicating that this approach may
offer a brief and cost-effective alternative to the treat-
ment of mental health difficulties. As such, there is
potential value in the evaluation of this type of interven-
tion for PGD.
Aims of the MCT trial
The aims of this study are to: (1) document the types of
metacognitive beliefs characteristic of those presenting
with PGD and use the information gleaned to guide the
development of an MCT programme specifically for
bereaved people; (2) investigate the efficacy of this meta-
cognitive grief therapy (MCGT) in reducing psycho-
logical distress by conducting a randomised controlled
trial; (3) evaluate the integrity of programme delivery
and treatment adherence; and (4) determine the appro-
priateness and acceptability of the MCGT programme
for individuals with PGD.
Hypotheses
1. The intervention group will report significantly
greater pre–post decreases in PGD symptomatology,
metacognitions, rumination, depression, anxiety and
stress, compared to the wait-list group.
2. The intervention group will report a significantly
greater pre–post increase in quality of life, compared
to the wait-list group.
3. For the intervention group, post-intervention changes
in PGD symptomatology, metacognitions, rumination,
depression, anxiety, stress and quality of life will be
maintained at the 3-month and 6-month follow-up.
4. Symptom change in the intervention group will be





The cognitive processes that control, monitor and
appraise thinking need to be specifically targeted to
treat PGD successfully.36 Therefore, we needed to
explore the metacognitions involved in PGD to ascertain
if the metacognitive model was applicable to PGD and
to find clinically relevant examples to incorporate into
the intervention that bereaved people could personally
relate to. A sequential methodological approach was
used to develop the MCGT treatment protocol. Step 1
involved a review of the literature to determine the
domains known to engage coping processes that disrupt
the grieving process (eg, cognitions, emotions, beha-
viours, etc). This information was used to inform the
interview questions for step 2. Step 2 involved semistruc-
tured interviews with psychiatrists/psychologists and
people with elevated PGD symptomatology to extract the
metacognitive beliefs driving maladaptive coping pro-
cesses within each domain. Step 3 used the information
gleaned to adapt ‘Metacognitive Therapy for Anxiety
and Depression’36 into a MCGT treatment that directly
targets the metacognitive beliefs involved in PGD.
Design: A qualitative research design using semistruc-
tured interviews was adopted to provide some topic con-
sistency, while allowing each interview to be adapted to
each informant.
Participants: A small sample was considered sufficient51
for the information required to refine the existing MCT
programme by Wells36 into a programme specifically for
PGD. Thus, psychiatrists/psychologists (N=6) willing to
share their knowledge and experience were purposively
recruited in order to understand the key metacognitions
pertaining to PGD. The findings were used iteratively to
refine the interview questions for participants with
PGD. In investigating people’s experiences and
cognitive processes, hearing the voices of people with
PGD was of utmost importance. Bereaved adults (N=5)
with elevated levels of PGD symptomatology (cut-off
score of ≥26) and social/occupational/functional
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impairment (determined by the PGD Scale;4 52) were
recruited through purposive sampling.
Procedure: Participants were interviewed (for approxi-
mately 60 min) using an interview schedule comprising
open-ended questions developed to extract metacogni-
tive beliefs across the domains derived from step 1. The
thoughts from each domain that triggered maladaptive
emotions or behavioural responses were explored (eg,
by asking what was driving that thought, emotion or
behaviour) to find the metacognitions associated with
them. Given the complexities and sensitivities of inter-
viewing bereft people, it was necessary to utilise a
person-centred method of interviewing so that the parti-
cipants conveyed their experiences from their own per-
spectives. The interviewer engaged the participant by
asking questions such as: “Can you give me an example
of things you do to feel closer to, to remember, or in
remembrance of (name)?”… “Why do you do this?”…
“What’s positive about that?”… “What’s negative about
that?” The interviews continued until saturation, as
defined by no new metacognitions arising. Participants
were compensated for their time with a gift voucher.
The interviews were audio recorded and transcribed
verbatim.
Analysis: The analysis process incorporated constant
comparison, which is the continual comparison of data,
within and between transcripts, so that similarities and
differences are revealed.53 This method was used to gen-
erate the identification and description of metacogni-
tions involved in PGD to inform the examples used in
the intervention.
Intervention content
The MCGT programme was developed as a modified
version of MCT, which targets the metacognitive beliefs
guiding maladaptive coping strategies, and eliminates
worry/rumination and fixed attention, which in turn
allows the metacognitive flexibility required for normal
cognitions to occur.36 MCT comprises three compo-
nents: engagement in therapy, MCT and maintenance.
The MCGT programme was produced by modifying
each of these components, manualised in
‘Metacognitive Therapy for Anxiety and Depression’
(see table 1; contact first author for details). Treatment
manualisation is important in evaluating the effects of a
specific treatment, as it allows treatment standardisation
and fidelity assessment and an operational definition of
the treatment.54 These tailored face-to-face sessions
(involving 10 or fewer participants) will run for 2 hours
once a week over 6 weeks. Two hours per session is
thought to assist participants to feel engaged in the
group process.55 Each group session will be facilitated by
the first author and a co-facilitator (both clinical psych-
ology trainees) and will be held at the Curtin University
Adult Psychology Clinic or a more geographically appro-
priate community centre, with refreshments provided.




Participants will be bereaved individuals aged 18 years or
more who are at least 6 months post the death of a sig-
nificant other. Participant inclusion criteria are: English
speaking; able to provide written informed consent;
presence of PGD (determined by PG-13 cut-off score4);
and if taking medication (namely, antidepressants or
other mood stabilisers), the medication must be stable
for 1 month prior to baseline assessment and dosage
and medication must remain the same throughout the
treatment period including follow-up. Participant exclu-
sion criteria will be: a high suicidal risk (determined by
the Mini International Neuropsychiatric Interview;
MINI56); current substance abuse or dependence;
current other psychological treatment; and a pre-existing
psychotic or bipolar disorder or neurological history,
according to DSM, 4th Edition, Text Revision (DSM
IV-TR) diagnostic criteria, as measured by the MINI.56
Sample size
Hypotheses 1–2 predict Group×Time interactions.
Assuming that these interactions are ‘moderate to large’
(f=0.31+), then 17 participants per group (N=34) should
give the generalised linear mixed model (GLMM) an
80% chance of capturing the interaction effects at an
α-level of 0.01 (allowing for Bonferroni corrections).
Table 1 Outline of ‘Metacognitive Grief Therapy’
Session Content
1 Normalise grief symptoms
Formulate metacognitive model of grief
Enhance awareness of metacognitions
Introduce metacognition self-monitoring
2 Explore the link between metacognitions,
emotions and behaviour




3 Detached mindfulness practice
Introduce attention training
Challenge positive metacognitive beliefs about
rumination/worry
4 Attention training practice
Challenge uncontrollability metacognitions and
positive beliefs about rumination
Explore metacognitive beliefs about avoidant
coping
Challenge unhelpful metacognitive beliefs about
pleasant activity scheduling




6 Detached mindfulness and attention training
practice
Relapse prevention
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Hypothesis 3 predicts significant therapeutic changes on
all outcomes between the pretest and 3-month follow-up
and between the pretest and 6-month follow-up.
Seventeen participants per group will provide an 80%
chance of capturing ‘moderate to large’ changes at a
Bonferroni-adjusted α-level of 0.01. The mediation
effects predicated in hypothesis 4 will be tested by esti-
mating the significance of the mediation pathway with a
bootstrapping procedure. Thirty-four participants should
sufficiently power this procedure. This sample size was
calculated with the aid of G×Power 3.58 A moderate to
large effect is assumed based on previous MCT interven-
tion studies.40 59
Recruitment
Participants from the metropolitan community of Perth,
Western Australia will be recruited through advertise-
ments in print media/websites/newsletters/flyers in pal-
liative care centres, bereavement groups, medical and
mental health centres, local shopping centre boards,
community newspapers, television and radio.
Measures
Descriptive measures
The following demographic information will be pro-
vided by each participant: age, gender, postcode,
general medical history, current psychological treatment,
cultural background, relationship with the deceased,
and employment status, date and cause of deceased’s
death.
The Millon Clinical Multiaxial Inventory (MCMI57); will
be used to describe the clinical personality patterns and
severe personality pathology of the population. It is a
175-item true/false self-report questionnaire designed to
assess indicators of DSM-V Axis II disorders. The MCMI
has shown test-retest reliability coefficients ranging from
0.77 to 0.87.57 60
Diagnostic measures
The Mini International Neuropsychiatric Interview (MINI56);
will be used to determine the presence/absence of
other possible comorbid disorders. The MINI is a short
diagnostic structured interview that provides a diagnosis
based on the DSM-V Axis I orICD, Revision 10 (ICD-10)
criteria. The suicidality section will be used to assess sui-
cidal risk and ideation. The MINI classifies levels of sui-
cidality into four groups: no suicidal risk, low suicidal
risk, moderate suicidal risk and high suicidal risk. It has
been shown to have high test-retest reliability (0.76–
0.93) and validity.61
The PGD Scale (PG-134); will be used as the primary
measure to determine the diagnostic status and
symptom severity of PGD. It is a 13-item self-report ques-
tionnaire that assesses PGD symptoms using a five-point
Likert scale (0–4) representing increasing levels of
symptom severity. One of the two ‘separation distress’
symptoms and five of the nine ‘cognitive, emotional,
and behavioural’ symptoms are required for diagnosis.
A total score (range: 0–44) is determined by summing
the scores. The PG-13 has shown adequate internal con-
sistency (Cronbach’s α=.82) and incremental validity.3 5
Self-report measures
Core Bereavement Items (CBI62); will be used as a general
measure of grief severity. The 17-item questionnaire is
scored on a four-point Likert scale ranging from 0
(never) to 3 (continuously), and has three subscales:
‘Images & Thoughts’ (7 items), ‘Acute Separation’ (5
items) and ‘Grief’ (5 items). A total score can be
obtained by summing the subscales ranging from 0 to
51. The scale has shown high internal consistency
(α=.92) and validity.62 63
Depression Anxiety Stress Scales-21 (DASS-2164); will be
used to measure symptoms of depression, anxiety and
stress. The 21-item questionnaire requires participants to
rate symptoms on a four-point Likert scale ranging from
0 (did not apply to me at all) to 3 (applied to me very
much, or most of the time). The scale consists of depres-
sion, anxiety and stress subscales that can be summed to
produce a total distress score. Higher scores indicate
higher symptomatology distress. High internal consist-
ency has been demonstrated for the depression (α=.94),
anxiety (α=.87) and stress (α=.91) scales and validity.64–67
The Repetitive Thinking Questionnaire (RTQ32); will be
used to assess all types of repetitive negative thinking.
The 31-item measure of transdiagnostic perseverative
thinking comprises two subscales: repetitive negative
thinking (27 items) and absence of repetitive thinking
(4 items). It is rated on a five-point Likert scale ranging
from 1 (not at all true) to 5 (very true). The RTQ has
been found to have high internal consistency (a=0.72–
0.93) and convergent validity.32
The Utrecht Grief Rumination Scale (UGRS27); will be
used to measure grief-specific rumination. This 15-item
self-report measure of recurrent, repetitive and self-
focused thoughts about the loss comprises five subscales:
thoughts about consequences and meaning of the loss;
thoughts about social support; ‘what-if’ questions; ‘why’
questions and thoughts about feelings. A total score can
be obtained by summing the subscales. Items are rated
on a five-point Likert scale ranging from 1 (never) to 5
(very often). The UGRS has been found to have excel-
lent internal consistency (α=.90), and validity.27
The Metacognitions Questionnaire-30 (MCQ-3068); will be
used to measure metacognitions. Each item on this
30-item self-report measure is rated on a four-point
Likert scale ranging from 1 (do not agree) to 4 (agree
very much) on five separate subscales: positive beliefs
about worry, negative beliefs about worry concerning
uncontrollability and danger, low cognitive confidence,
need to control thoughts, and cognitive self-
consciousness.68 A total MCQ-30 score is obtained by
summing the subscales. A high score indicates stronger
beliefs about the need to control and the negative con-
sequences associated with intrusive thoughts. Internal
consistency across individual subscales on the MCQ-30
Wenn J, et al. BMJ Open 2015;5:e007221. doi:10.1136/bmjopen-2014-007221 5
Open Access
group.bmj.com on May 26, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
has been found to range from 0.72 to 0.93 with a total
internal consistency of 0.93 and a test-retest reliability of
0.75.35 68
The Quality of Life Enjoyment and Satisfaction
Questionnaire-18 (Q-LES-Q-1869); will be used to measure
general quality of life and specific life domain levels of
enjoyment and satisfaction. It is an 18-item self-report
scale measuring specific life domains: physical health,
subjective feelings, leisure time activity, social relation-
ships, and satisfaction with medication. A five-point
Likert scale ranging from 1 (not at all) to 5 (all the
time) is used for responses. General quality of life index
is measured by summing the 18 items. The Q-LES-Q-18
has good construct and concurrent validity, as well as
high internal consistency ranging from 0.82 to 0.94 and
test-retest reliability ranging from 0.71 to 0.83.69
Therapist measure
The Clinical Global Impression (CGI-Improvement Scale
(CGI-IS70); will be used to rate each participant’s
improvement or decline in post-treatment assessment.
It is a global rating of improvement in clinical disorders
ranging from 1 (very much improved) to 4 (no change)
to 7 (very much worse). It has shown high inter-rater
reliability (0.87–0.99). To limit experimenter effects, the
first author and an independent experienced psycholo-
gist will use this scale to compare baseline and follow-up
interviews. Treatment response will be indicated by a
rating of 1 (completely recovered), 2 (very much better)
or 3 (much better). Inter-rater reliability will be calcu-
lated using Cohen’s κ statistic.71
Trial design
A randomised experimental pretest/posttest wait-list
control group design with a 3-month and 6-month
follow-up for the intervention group will be used to
evaluate the effects of MCGT on PGD. The outcome
variables are anxiety, stress and depression (DASS-21);
grief distress (PG-13/CBI); rumination (RTQ/UGRS),
metacognitions (MCQ-30) and quality of life
(Q-LES-Q18). The independent variables are the group
condition (MCGT; WL), and time (pretest, posttest,
3-month and 6-month follow-up). A study design flow
chart is shown in figure 1.
Procedure
Following ethical approval from Curtin University
Human Research Ethics committee, participants who
express an interest to take part in the study will be
screened by telephone. Those who meet inclusion
Figure 1 The ‘Metacognitive
Grief Therapy (MCGT) Program’
proposed design and progress
phases.
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criteria will then attend an individual assessment session
where they will read and sign consent forms, complete
the MCMI and be interviewed using the MINI. Eligible
participants will then be randomly allocated to the inter-
vention or wait-list control condition via computer gen-
erated randomised numbers. The self-report measures
will be conducted at preintervention and thereafter
post-tests will be conducted at treatment completion,
and at 3-months and 6-months from treatment comple-
tion for the intervention group only (via post or assist-
ance from a psychology graduate trainee). Only the
primary researcher will have access to the participants’
data, which will be coded with an ID number and cross
referenced in a university database to maintain confi-
dentiality and preserve anonymity beyond the primary
researcher. Any identifying information (ie, consent
forms and demographic details) will be kept separate
from the data and locked in a secured university filing
cabinet for a period of 5 years, after which it will be
destroyed. Participant compensation will be in the form
of a gift voucher at post-test and 6-month assessment
points. Following the post-test, MGCT will be offered to
the wait-list control group, to ensure they also benefit
from participation in the study. Participants in the wait-
list control groups will receive a monthly phone call
or email to ensure waiting for treatment is not detrimen-
tal and that they remain in the study. Treatment partici-
pants wishing to drop out of the study and wait-list
participants demonstrating a need for immediate inter-
vention will be withdrawn from the study and provided
appropriate referral information.
Data analysis
A GLMM will be used to test H1 and H2. The GLMM is
‘generalised’ in the sense that it can handle outcome
variables with markedly non-normal distributions;
GLMM is ‘mixed’ in the sense that it includes random
and fixed effects. The present GLMM includes one cat-
egorical random effect (participant), one categorical
fixed effect (group: intervention, control), one ordinal
fixed effect (time: pretest, post-test, 3-month follow-up,
6-month follow-up), and the Group×Time interaction.
A second GLMM will be developed to test H3. This
GLMM will include one categorical random effect (par-
ticipant) and one ordinal fixed effect (time: pretest,
post-test, 3-month follow-up, 6-month follow-up) will be
implemented through SPSS’s (V.22) GENLINMIXED
procedure. In order to optimise the likelihood of con-
vergence, a separate GLMM analysis will be run for each
of the outcome measures (PG-13, CBI, DASS, RTQ,
UGRS, MCQ-30, Q-LES-Q-18). Analysing each outcome
independently of the others will inflate the family-wise
error rate and the per-test α will therefore need to be
corrected to control the inflation. In order to conserve
statistical power, the α correction will be applied within
groups of conceptually related outcomes rather than
across the entire set of outcomes.
GLMM will assume a normal probability distribution
for the outcome and link it to the fixed effects (group,
time, group×time) with an identity function.72 If the
outcome does not have a normal distribution, then the
parameter estimates of the covariance matrix will be
computed with robust statistics. In order to make the
model robust to violations of sphericity, the covariance
matrix will be changed from the default of compound
symmetry to autoregressive.
The mediation effects predicted in H4 will be tested
with structural equation modelling in order to adjust for
the relatively low reliabilities associated with change
scores. The significance of the mediation pathways will
be tested with a bootstrapping procedure based on 1000
draws as implemented by Mplus (V.5.2). Assuming ‘mod-
erate to large’ mediation effects as per previous MCT
intervention studies,40 59 G×Power 373 estimates that 34
participants will sufficiently power these tests. The medi-
ation model will include one binary independent vari-
able (group: intervention vs control), inputting to two
mediating variables (metacognition and rumination),
which then input to one outcome variable (eg, PGD).
To conserve statistical power, separate mediation models
will be tested for each of the other outcome variables.
The mediating variables will be pre–post change scores,
and the outcome variables will be pre-follow-up change
scores.
Randomisation to groups should ensure that the
groups are matched in terms of potentially confounding
demographic covariates; but this process can be under-
mined by participant attrition. We will therefore attempt
to identify confounding demographic variables (ie,
demographic variables that show between-group differ-
ences and are correlated with the outcome at any of the
assessment points) and control for them statistically by
including them as covariates in the GLMM analyses.
Pretest differences on the outcome variables are con-
trolled by including pretest scores as the first level of the
time factor in the GLMM analyses.
Participant attrition occurs in longitudinal data irre-
spective of the number of sessions completed.
Participants who miss two treatment sessions will be
regarded as dropouts. To optimise power, the outcome
data for all participants will be analysed (regardless of
the number of sessions completed) using the ‘dose’ (ie,
number of sessions) as a covariate in the GLMM.
Compared to the traditional statistical procedures for
analysing behavioural change (eg, repeated measures
analysis of variance), GLMM is less sensitive to partici-
pant attrition, does not rely on participants providing
data at every assessment point, can deal with unequally
spaced data collection points, is robust to unequal group
sizes, does not require equal variances at each time point,
does not require equal covariance between all pairs
of time points (ie, sphericity), and is able to account for
correlations among repeated measurements.72 GLMM
will analyse all pretest scores on the outcomes regardless
of whether participants attend posttest and follow-up
Wenn J, et al. BMJ Open 2015;5:e007221. doi:10.1136/bmjopen-2014-007221 7
Open Access
group.bmj.com on May 26, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
assessments. This reduces sampling bias and the need to
replace missing data. To assess if dropouts differ with
completers they will be compared on demographics and
baseline outcome measures. Treatment effect sizes on all
outcomes will be calculated using Cohen’s d statistic.74
Once an intervention effect has been established at the
group level, an estimate of the clinical significance of the
change will be calculated using the reliable change
index. This will be assessed by calculating the degree
to which participants change on the outcome variable
divided by the SE of the difference between the
pretest and posttest scores. A Reliable Change Index
greater than an absolute value of 1.96 will reflect a reli-
able change.75
Phase 3
Programme integrity and content compliance
The first author and the group co-facilitator (both clini-
cal psychology trainees) will be trained by a clinical
psychologist MCT specialist. According to the
intention-to-treat principle, researchers must assess
protocol adherence in order to provide an unbiased
assessment of treatment efficacy.73 To evaluate the integ-
rity of the programme delivery and treatment adherence,
each group session will be checked to ensure it is deliv-
ered in accordance with the MCGT session-by-session
module overview. This involves the independent comple-
tion of a programme implementation effectiveness
checklist by the first author and co-facilitator at the com-
pletion of each session. Each item will be rated using a
10-point Likert scale. A minimum of 10% of the video
recordings for each session will also be reviewed by a
supervisor with a clinical psychology background for
protocol adherence. Inter-rater reliability will be calcu-
lated using the ‘average measures’ intraclass correlation
using the ‘two way random model’ in conjunction with
the ‘consistency procedure’.76
Social validity
At programme completion, the social validity of the
entire programme will be measured using the
Programme Satisfaction Questionnaire adapted from a
depression and anxiety prevention programme.77 The
participants will complete questionnaires comprising an
overall programme rating (section A), the practicality of
the skills taught (section B) and a qualitative interview
(section C). Sections A and B will be rated on a five-point
Likert scale ranging from 1 (not at all) to 5 (very much).
The five open-ended questions in section C allow partici-
pants to identify programme components least and most
enjoyed and information most utilised. The question-
naires will determine the appropriateness and acceptabil-
ity of the programme. Descriptive statistics will be used to
analyse the quantitative responses of the Programme
Satisfaction Questionnaire. The open-ended qualitative
responses to each question will be summarised.
DISCUSSION
There is very robust evidence demonstrating that PGD
differs from normal grief in terms of symptoms, aeti-
ology, outcomes, course and response to treatment4 and
that people with PGD experience self-blame78 and are
under-represented in mental health services.5 Existing
interventions show some promise, but their effectiveness
is limited. Recent studies suggest there is a need for
treatments to incorporate techniques that deal with
rumination, as it is associated with and predictive of
PGD.27 79 Given the severity of PGD, it is important to
address directly the factors involved to limit the extent
to which the death of a significant other may constitute
a broader risk to bereaved individuals’ long-term health
outcomes.
This paper is a comprehensive description of the
methodology used to develop, implement and evaluate
MCGT, a MCT programme for PGD. MCT is an effica-
cious treatment for several psychological disorders (sup-
porting the regulation of cognitive processes); however,
no research has been conducted on the effectiveness of
this treatment for people with PGD. It is proposed that
an intervention based on the metacognitions of this
subset of bereaved individuals will target the dysfunc-
tional coping processes (eg, rumination, worry and
avoidance behaviours) that keep attention focused on
distressing and unhelpful information, depleting the
processing resources required for thinking to return to
its normal trauma free status.
The proposed study will evaluate the efficacy of man-
ualised MCGT to reduce PGD symptoms. This study will
determine if MCGT is likely to be effective in reducing
PGD symptoms and will establish the mechanisms by
which the intervention may be effective. The study will
also determine if MCGT is able to enhance the quality
of life for people with PGD and if the intervention is
acceptable to them. IF MCGT is not effective, the study
will identify the factors that contributed to a negative
outcome.
This research has implications for healthcare profes-
sionals who work with bereaved clients. A validated short
intervention that is acceptable to bereaved people would
benefit services where long-term care is not an alterna-
tive.6 The proposed research is innovative because it will
provide much needed empirical evidence to guide
future programmes that target PGD and, if MCGT
proves to be effective, it will provide a precise interven-
tion that ameliorates PGD symptomatology. As such, this
study makes an important contribution to theory and
practice.
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